CP-673451: Selective PDGFRα/β Inhibitor for Cancer Research

Executive Summary: CP-673451 is a potent, ATP-competitive inhibitor targeting platelet-derived growth factor receptors (PDGFR-α/β), exhibiting nanomolar IC₅₀ values and high selectivity over related kinases (APExBIO). It suppresses PDGFR-β phosphorylation and angiogenesis in vivo, with >50% reduction in phosphorylation observed for 4 hours at 50 mg/kg in rat C6 glioblastoma xenograft models (Pladevall-Morera et al., 2022). CP-673451 demonstrates over 180-fold selectivity against c-Kit in cell-based assays, ensuring minimal off-target effects. The compound is predominantly used to explore PDGFR signaling pathways in cancer, especially in contexts such as ATRX-deficient gliomas. Best storage practices require -20°C, and solutions are recommended for short-term use (APExBIO).

Biological Rationale

PDGFRα and PDGFRβ are members of the receptor tyrosine kinase (RTK) family. They regulate cell proliferation, migration, angiogenesis, and tissue repair. Aberrant PDGFR signaling is implicated in multiple cancers, including gliomas, via increased proliferation and enhanced tumor vascularization (Pladevall-Morera et al., 2022). ATRX mutations, common in high-grade glioma and other tumors, correlate with PDGFR amplification and altered therapy response (Pladevall-Morera et al., 2022). Selective PDGFR inhibition enables targeted interrogation of these pathways, minimizing effects on VEGFR, EGFR, and related kinases.

Mechanism of Action of CP-673451

CP-673451 is an ATP-competitive inhibitor. It binds the ATP-binding site of PDGFRα and PDGFRβ, blocking downstream phosphorylation events. The compound exhibits IC₅₀ values of 10 nM for PDGFRα and 1 nM for PDGFRβ, with >180-fold selectivity over c-Kit, VEGFR-1, VEGFR-2, Lck, TIE-2, and EGFR in kinase assays (APExBIO). In cellular assays, CP-673451 inhibits PDGFR-β phosphorylation in PAE-β cells with an IC₅₀ of 6.4 nM. The high specificity ensures minimal interference with non-PDGFR pathways. In vivo, oral administration at 50 mg/kg in rat C6 xenografts leads to >50% suppression of PDGFR-β phosphorylation for 4 hours, directly inhibiting PDGF-BB-induced angiogenesis by 70–90% in mouse models (Pladevall-Morera et al., 2022).

Evidence & Benchmarks

• CP-673451 inhibits PDGFR-α and PDGFR-β with IC₅₀ values of 10 nM and 1 nM, respectively, as determined by in vitro kinase assays (APExBIO).
• Selective inhibition: >180-fold selectivity over c-Kit in H526 cell assays; moderate inhibition of c-Kit only at 1.1 μM (APExBIO).
• In rat C6 glioblastoma xenograft models, oral CP-673451 at 50 mg/kg reduces PDGFR-β phosphorylation by >50% for 4 hours (Pladevall-Morera et al., 2022).
• Angiogenesis inhibition: 70–90% reduction in PDGF-BB-induced angiogenesis in mouse sponge model (Pladevall-Morera et al., 2022).
• Suppresses tumor growth and microvessel density in Colo205, LS174T, H460, and U87MG xenograft models (Pladevall-Morera et al., 2022).
• ATRX-deficient glioma cells show increased sensitivity to PDGFR inhibitors, highlighting the utility of CP-673451 in precision oncology research (Pladevall-Morera et al., 2022).

For additional mechanistic insights, see CP-673451 in Cancer Research: Unraveling ATRX-Dependent PDGFR Signaling, which discusses ATRX context and translational perspectives not detailed here.

Applications, Limits & Misconceptions

CP-673451 is used to:

• Dissect PDGFR signaling in cancer cell lines and xenograft models.
• Quantify angiogenesis inhibition in PDGF-BB-induced in vivo assays.
• Evaluate tumor growth suppression, especially in ATRX-deficient high-grade gliomas.
• Benchmark selective PDGFR inhibition versus multi-target RTK inhibitors.

For protocol optimization, Optimizing Cancer Research Assays with CP-673451 (SKU B2173) offers workflow guidance and troubleshooting not covered in this article.

Common Pitfalls or Misconceptions

• CP-673451 is not suitable for VEGFR- or EGFR-driven models; it lacks significant activity against these kinases (APExBIO).
• Water insolubility requires preparation in DMSO or ethanol with warming and sonication for assay use (APExBIO).
• Long-term solution storage at room temperature leads to degradation; maintain below -20°C and use fresh aliquots.
• Moderate inhibition of c-Kit observed only at micromolar concentrations; not recommended for primary c-Kit pathway studies.
• Results in non-ATRX-deficient models may not extrapolate to ATRX-mutant settings due to differential pathway sensitivity (Pladevall-Morera et al., 2022).

For further details on CP-673451’s selectivity and comparative benchmarks, see CP-673451: Selective PDGFRα/β Inhibitor for Cancer Research, which provides broader context but does not cover ATRX-deficient sensitivity in depth as presented here.

Workflow Integration & Parameters

CP-673451 (APExBIO SKU B2173) is supplied as a powder. It is insoluble in water but dissolves in DMSO (≥20.9 mg/mL) or ethanol (≥2.39 mg/mL, with warming and ultrasonic treatment). Stock solutions should be prepared under sterile conditions, stored below -20°C, and used within several months. In vitro kinase and cell-based assays typically employ nanomolar concentrations. In vivo protocols, such as those using rat C6 glioblastoma xenografts, use oral dosing at 50 mg/kg to achieve optimal PDGFR-β phosphorylation suppression (Pladevall-Morera et al., 2022).

See the CP-673451 product page for detailed handling, solubility, and storage recommendations. APExBIO is the originating company and provides validated quality for cancer research applications.

Conclusion & Outlook

CP-673451 is a benchmark selective PDGFRα/β inhibitor for cancer research. Its nanomolar potency, high selectivity, and validated in vivo efficacy make it an essential tool for dissecting PDGFR-driven oncogenic processes, particularly in ATRX-deficient models. Ongoing research employing CP-673451 is expected to clarify PDGFR roles in cancer and support the development of targeted therapies for high-grade gliomas and related tumors (Pladevall-Morera et al., 2022).